2022 World Conference on Lung Cancer (ePosters)-EP08.01-068. Going for the Ligand After a Stint With the Receptor: Can Switching Target From PD-1 to PD-L1 (Or Vice-Versa) Be Beneficial?

EP08.01-068. Going for the Ligand After a Stint With the Receptor: Can Switching Target From PD-1 to PD-L1 (Or Vice-Versa) Be Beneficial?

Back to course

Pdf Summary

Northwell Health is New York State's largest healthcare provider and private employer. They are committed to improving community health, providing quality clinical care, educating healthcare professionals, conducting biomedical research, promoting health education, and caring for the entire community regardless of their ability to pay.<br /><br />The document discusses a study conducted by Northwell Health on the efficacy of switching the target of immune checkpoint inhibitors (ICI) from the receptor to the ligand in non-small cell lung cancer (NSCLC) patients. ICIs have transformed the standard of care for NSCLC patients without actionable mutations and can provide a sustained response. However, when patients progress on ICIs, treatment options are limited. The study explores the potential benefit of switching the checkpoint target after progression or intolerance to the first ICI.<br /><br />The retrospective analysis included NSCLC patients who received PD-1/PD-L1 inhibitors and were subsequently treated with the other inhibitor after progression or intolerance. The median progression-free survival (PFS) of the first ICI was calculated, as well as the PFS of the second ICI. The results showed that treatment with a second ICI after failure on the first may provide benefit in NSCLC, with median PFS comparing favorably to single-agent chemotherapy. Patients who were alive without progression at 3 months on the second ICI and those who experienced adverse events with the first ICI did particularly well.<br /><br />The study concluded that using a second ICI should be considered for advanced NSCLC patients with limited treatment options. Smoking status, comorbid conditions, gender, and history of receiving chemotherapy did not significantly correlate with PFS. Further studies are recommended to explore the impact of different specific ICIs and to compare progression-free survival in patients who received chemotherapy.<br /><br />In summary, the study by Northwell Health suggests that switching the target of immune checkpoint inhibitors may be beneficial for NSCLC patients who have progressed or experienced intolerance to the first inhibitor. Further research is needed to understand the impact of specific ICIs and the role of chemotherapy in this treatment approach.

Asset Subtitle

Nida Khan

Meta Tag

Speaker Nida Khan

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

Northwell Health

New York State

healthcare provider

clinical care

biomedical research

health education

immune checkpoint inhibitors

NSCLC patients

progression-free survival

chemotherapy